Real-world economic value of a 21-gene assay in early-stage breast cancer.

CONCLUSIONS: Universal GEP testing of women 70 years or younger with stage II or grade 2/3 lymph node-negative breast cancers would result in lower outpatient costs, inclusive of the diagnostic test, within the first 6-month episode of care.
PMID: 29261249 [PubMed - in process]

Source: The American Journal of Managed Care - December 1, 2017 Category: Health Management Authors: Waintraub SE, McNamara D, Graham DMA, Pecora AL, Min J, Wu T, Noh HG, Connors J, Pe Benito R, Choi K, Schultz E, Goldberg SL Tags: Am J Manag Care Source Type: research